Equilibre BioPharmaceuticals Corp. — Form D

Equilibre BioPharmaceuticals Corp. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2022-01-20. The offering totals $25.0M, of which $15.9M was reported sold. Industry: Pharmaceuticals.

Offering

Issuer

Officers, directors & promoters (20)

NameRoleLocation
Philip BarachDirectorPortland, ME
David FriedmanDirectorNEW HAVEN, CT
Steven GordonDirectorNew York, NY
Francois MaisonrougeDirectorNew York, NY
Joel MarcusDirectorSouth San Francisco, CA
Peter SimonDirectorDenver, CO
Samuel WaksalDirectorNew York, NY
Steven GordonExecutive OfficerNew York, NY
Samuel WaksalExecutive OfficerNew York, NY
Christopher M ThornDirectorNew York, NY
Christopher M ThornExecutive OfficerNew York, NY
Christina A RamirezDirectorNew York, NY
Peter M SimonDirectorNew York, NY
Francois A MaisonrougeDirectorNew York, NY
Sam WaksalExecutive OfficerNew York, NY
DAVID A FRIEDMANDirectorEVANSTON, IL
Steven N GordonDirectorNew York, NY
Steven N GordonExecutive OfficerNew York, NY
PHILIP A BARACHDirectorLOS ANGELES, CA
PHILIP A BARACHExecutive OfficerLOS ANGELES, CA

Other filings by this issuer (3)

FiledFormOfferingSold
2022-12-01D$6.0M$6.0M
2022-12-01D/A$6.0M$6.0M
2020-11-12D$35.8M$25.8M

More